Inhibikase Therapeutics, Inc.

IKT Nasdaq SEC CIK 1750149
Follow Inhibikase Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$20.5M −71.6% vs same quarter last year
EPS, diluted −$0.10 +23.1% vs same quarter last year
Operating cash flow −$17.4M −63.8% vs same quarter last year
Operating income −$22.2M −74.1% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$48.3M
FY24$0−$27.5M
FY23$260.5K−$19M
FY22$123.4K−$18.1M
FY21$3.1M−$14.8M
FY20$698.5K−$2.8M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23−7712%−7304.7%
FY22−14686.2%−14625.9%
FY21−476.2%−476.9%
FY20−403.5%−407.7%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$27.8M
FY24−$19.1M
FY23−$18.1M
FY22−$17.6M
FY21−$14.3M
FY20-
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Inhibikase Therapeutics
  • Healthcare median
−15000%−10000%−5000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearInhibikase TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23−7304.7%−58%
FY22−14625.9%−80.4%
FY21−476.9%−71.8%
FY20−407.7%−62.2%
FY19-−46.2%